Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Raises $82.5M in Private Financing

NEW YORK — 23andMe has raised $82.5 million through an equity sale, according to a filing late last week with the US Securities and Exchange Commission.

According to the filing, 23andMe offered a total of $85 million worth of equity.

The firm confirmed that the Series F round was led by Sequoia Capital and NewView Capital, which was reported yesterday by Bloomberg

In January, the Sunnyvale, California-based direct-to-consumer genetic test developer and ancestry information firm laid off about 100 of its employees — roughly 14 percent of its workforce at the time — amid a restructuring of its consumer business.

In mid-2018, 23andMe raised about $300 million in an equity offering. The year before, the company closed an approximately $250 million financing round led by Sequoia Capital.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.